Vor Biopharma Inc. (NASDAQ:VOR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Vor Biopharma Inc. (NASDAQ:VOR) have earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $50.6667.

A number of research firms have recently commented on VOR. TD Cowen started coverage on shares of Vor Biopharma in a report on Wednesday, December 17th. They issued a “buy” rating on the stock. Wells Fargo & Company began coverage on shares of Vor Biopharma in a research report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price objective for the company. Wedbush upped their target price on shares of Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Finally, Citigroup assumed coverage on shares of Vor Biopharma in a research note on Friday, January 9th. They set a “buy” rating and a $50.00 price target for the company.

Vor Biopharma Price Performance

Shares of Vor Biopharma stock opened at $18.05 on Monday. The stock’s fifty day moving average is $14.22 and its two-hundred day moving average is $17.44. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80. The company has a market capitalization of $881.74 million, a PE ratio of -0.05 and a beta of 1.92.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Ariose Capital Management Ltd bought a new position in shares of Vor Biopharma during the 3rd quarter worth $5,368,000. Fcpm Iii Services B.V. bought a new stake in shares of Vor Biopharma in the third quarter valued at about $18,496,000. Jane Street Group LLC bought a new stake in shares of Vor Biopharma in the first quarter valued at about $140,000. Susquehanna Portfolio Strategies LLC purchased a new stake in Vor Biopharma in the fourth quarter worth about $134,000. Finally, XTX Topco Ltd purchased a new stake in Vor Biopharma in the second quarter worth about $66,000. 97.29% of the stock is owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).